Jazz Pharmaceuticals plc (JAZZ) announced on Thursday that its drug Zanidatamab-hrii, branded as Ziihera 50 mg/ml for intravenous injection, has received a category 2A recommendation from the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for the treatment of biliary tract cancers (BTC).
Ziihera is a bispecific antibody indicated for use in adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC. Jazz Pharmaceuticals emphasized that this endorsement by the NCCN reinforces Ziihera's role in addressing biliary tract cancer.
As of the latest trading session, Jazz's shares are priced at $122.25, reflecting a decrease of 0.98 percent on the Nasdaq.
